Recent evidence suggests the involvement of nitric oxide (NO) in inflammation and demyelination in the brain. To test this hypothesis, we measured NOmarkers in the cerebrospinal fluid from patients with bacterial meningitis (BM), aseptic meningitis (AM), multiple sclerosis (MS), and Guillain-Barre syndrome (GBS). Subjects with non-inflammatory neurologic diseases served as the controls. NOmarkers were cyclic guanosine monophosphate (CGMP)measured with an enzymeimmunoassay, and nitrite and nitrate measured with the Griess reaction. Except for BM, CGMP was not increased in AM,MSor GBScompared with the controls. Nitrite and nitrate were unaltered in any of the groups studied. These results do not support the hypothesis that NOis increased in the brain in meningitis, MSor GBS. Otherwise CGMP, nitrite and nitrate in the cerebrospinal fluid do not reflect the increase in NOin the brain. (Internal Medicine 34: 734-737, 1995) 
Introduction
Nitric oxide (NO) plays multiple roles in the brain: as a neurotransmitter (1) , as a vasodilator (2) , and as an immune mediator (3) . In the immune system, NOhas both protective (4) and injurious actions (5, 6) but its role in brain diseases remains unknown. In the animal models of meningitis (3) and encephalitis (7), the mRNA expression of inducible NOsynthase (iNOS) is increased. In humans, Visser et al (8) reported that patients with meningococcal meningitis have greatly increased concentrations of NOmetabolites in the cerebrospinal fluid (CSF) while Milstien et al (9) observed only a mild increase in patients with meningitis. NOis implicated also in multiple sclerosis (MS). NOmediates toxicity toward oligodendrocytes, resulting in demyelination in vitro (6). NOis localized in the spinal cord of mice with experimental allergic encephalomyelitis (EAE) ( 10) , the animal model of MS. mRNAexpression of iNOS is increased not only in EAE(7), but also in the brain of patients with MS(1 1). Guillain-Barre syndrome (GBS) is another inflammatory neurologic disease which is different from meningitis and MS.
Although NO-inducible cytokines are increased in the CSF( 1 2) and serum (13) in GBS, there has beenno study onNOin GBS. The present study was undertaken to determine if NOis increased in meningitis, MSand GBSand if there is any difference in NO production in these diseases. Wemeasured cyclic guanosine monophosphate (CGMP), nitrite (NO2~) and nitrate (NO3~), commonmarkers of NO(14) , in CSF from patients with bacterial meningitis (BM), aseptic meningitis (AM), MS and GBS.
Patients and Methods
The patients were divided into five groups, (i) The control group consisted of29 patients (age 54.0±3.8 years) with one of the following non-inflammatory neurologic diseases: tension headache, cervical spondylosis, myotonic dystrophy, amyotrophic lateral sclerosis, spinocerebellar degeneration or Par- age 34.6+4.1 years; n=13. All had active disease which was defined as an acute exacerbation with the occurrence of new neurologic symptoms lasting more than 24 hours, (v) GBS: age 34.0+4.8 years; n=7. All had rapidly progressive motor weakness of lower and upper extremities, areflexia and mild sensory signs. CSF showed normal cell counts in all subjects. The concentration of protein was increased in five patients. Two patients had normal CSF protein initially with a later rise in subsequent lumbar punctures. CSF samples, obtained by lumbar puncture, were frozen immediately and stored at -80°C. Total protein, glucose, white blood cell counts and the presence of bacteria were tested by routine laboratory methods. The CGMP concentration was assayed in duplicate with a commercial enzyme immunoassay kit (Amersham). The samples (50 jul), acetylated in an acetic anhydride-triethylamine mixture, was incubated with 1 00 jul of rabbit anti-CGMP serum at 4°C for 2 hours. Then 100 (il of CGMP-peroxidase conjugate wasadded and the sampleswere incubated at 4°C for 1 hour. After aspiration of unbound conjugate, 200 jlxI ofenzyme substrate was added. A blue color, which can be read at 630 nm, developed after the incubation at room temperature for 30 minutes.
NO2~and NO3~(the latter after reduction to NO2~) were measured by a microplate version of the Griess reaction (14). NO3~was reduced to NO2~in the presence of 0. 1 U/ml nitrate reductase (Aspergillus species; Boehringer-Mannheim). Then Statistical analysis was performed by means of KruskalWallis test for multiple comparisons. Twoindividual mean values were compared post hoc with Dunnett's Mest. Regression analysis was done by the method of least squares.
Results Figure 1 shows that the markers of NOwere generally unaltered in the patient groups studied. The CGMPconcentration in CSF in the control group was 2.4+0.4 nM. With the exception of BM(10.4±2.6 nM, *p<0.05), CGMPwas not increased in AM(2.5+1.1 nM), MS (2.3±0.6 nM) or GBS (1.8±0.6 nM). NO2"andNO3-were unaltered inBM (0.56±0.08, CGMP,NO2~and NO3~did not correlate with the number of white blood cells in CSF or the age of the subjects in any of the groups studied (-0.305<r<0.259).
There was no correlation between CGMPand NO2" or NO3" (r=-0.006, -0.025, respectively).
Discussion
In the present study, CGMP,NO2~and NO3~, were generally unaltered in the groups studied. The only significant change was the increase in CGMP in BM. In the animal model of meningitis, Campbell et al (3) reported that the expression ofiNOSmRNA is increased in the glia of the inflammatory lesions. Visser et al (8) reported that NO2~and NO3~are increased in CSFin patients with meningococcal meningitis while Milstien et al (9) observed only a mild increase in CSF NO3~in patients with BMand AM.In the present study, NO2"and NO3~in BMand AMremained similar to those in the controls. Multiple factors, i.e. pathogens, treatment and the status of the patients, could explain these discrepant results. For example, Visser et al (8) focused on meningococcal meningitis and studied 94 patients whereas our BM group included only two patients with meningococcal meningitis. It may be that only particular bacteria increase NOproduction in the brain. Milstien et al (9) question ifNO2~andNO3~in CSF originate in the brain in meningitis. They indicated that the serum nitrate concentration, much greater than that in CSF, may contribute to the increase in CSF nitrate through the damaged blood-brain barrier. Another problem with NO2~and NO3~as NOmarkers is that they derive not only from the metabolism of NObut also from other sources, such as food (16). CGMP maynotbe a specific marker of NOin vivo as it is in vitro (14). The increase in CGMPwithout an increase in NO2" and NO3~, as in BMin the present study, suggests that the activation of guanylate cyclase is caused by another molecule (17). The lack of correlation between CGMPand NO2~and NO3~in the present study is additional evidence for the activation of guanylate cyclase without NO.
As in inflammatory diseases in other tissues, NOproduction is considered to be increased in meningitis (3) but previous studies have not all supported this hypothesis. First, investigators are not necessarily successful in inducing high-output NO synthesis from humancells cultured in vitro by treatment protocols with cytokines that are highly effective with rodent cells (18, 19) . Secondly, some inflammatory cytokines decrease constitutive NOS(20) but increase the other type, iNOS. Moreover, other cytokines which are increased in the CSFfrom patients with BMinhibit even iNOS (21). These reciprocal effects of cytokines can obscure the increase in NO, if any. Lin et al (10) showed that NOis localized in the spinal cord of mice with EAE. iNOS mRNAis increased both in the mouse brain with EAE (7) and in the brain of patients with MS(1 1). Although these studies suggest that NOis increased in the MS brain, NOmarkers in CSF were not increased in the present study. One explanation is that the increase in NOis sequestered in a closed compartmentof the brain and is not reflected to the CSFspace. This is not the case with GBSin which the demyelinating lesion is exposed to the CSF space. To our knowledge, there is no study on NOin GBSalthough NO-inducible cytokines are increased in CSF (12) and serum (13) in GBS.
In conclusion, the present study does not indicate an increase in NOin the brain in meningitis, MSor GBS; or CGMP, NO2ã nd NO3~in the CSFare not reflective of the increase in NOin the brain.
